2023
DOI: 10.3390/pharmaceutics15041242
|View full text |Cite
|
Sign up to set email alerts
|

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate

Abstract: Antibody–drug conjugates (ADCs) are a potential and promising therapy for a wide variety of cancers, including breast cancer. ADC-based drugs represent a rapidly growing field of breast cancer therapy. Various ADC drug therapies have progressed over the past decade and have generated diverse opportunities for designing of state-of-the-art ADCs. Clinical progress with ADCs for the targeted therapy of breast cancer have shown promise. Off-target toxicities and drug resistance to ADC-based therapy have hampered e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(4 citation statements)
references
References 102 publications
0
4
0
Order By: Relevance
“…Tumoral microenvironment, changes in pH or expression of different immune cells around the tumor can activate the ADC and detach the drug outside the cells, conferring a greater effect. This mechanism is particularly important for solid tumors since they tend to have a heterogeneous expression of target antigen among cells (Figure 2) [7,8]. The third part of ADCs, the cytotoxic drug, also known as payload, is responsible for inducing apoptosis and tumor cell death.…”
Section: Structure and Mechanisms Of Action Of Adcsmentioning
confidence: 99%
“…Tumoral microenvironment, changes in pH or expression of different immune cells around the tumor can activate the ADC and detach the drug outside the cells, conferring a greater effect. This mechanism is particularly important for solid tumors since they tend to have a heterogeneous expression of target antigen among cells (Figure 2) [7,8]. The third part of ADCs, the cytotoxic drug, also known as payload, is responsible for inducing apoptosis and tumor cell death.…”
Section: Structure and Mechanisms Of Action Of Adcsmentioning
confidence: 99%
“…Besides, non-internalizing ADCs usually do not require the overexpression of cancer cell surface antigens and can take advantage of several physiological features of the tumor microenvironment (such as pH and hypoxia) for targeted delivery [ 44 ]. Thus, non-internalizing ADCs are good candidates to target cancers with dense tumor stroma, such as TNBC and pancreatic ductal adenocarcinoma (PDAC) [ 45 ].…”
Section: Adc: the Concept History And Developmentmentioning
confidence: 99%
“…Moreover, it is worth highlighting that the Golgi apparatus has sparked interest as a potential molecular target in breast cancer therapy. A growing number of therapeutic avenues, including antibody–drug conjugates, nanoparticles equipped to deliver antibody drugs, conjugate drug therapies, and advanced immunotherapies, are under scrutiny to optimize cancer patient outcomes [ 69 ]. The selection of a treatment strategy is contingent on myriad factors, including the patient’s tumor subtype, its stage, and substage classification.…”
Section: Possible Therapeutic Targets Regarding Breast Cancermentioning
confidence: 99%